8 results on '"Bosch-Nicolau, Pau"'
Search Results
2. Evaluation of two different strategies for schistosomiasis screening in high-risk groups in a non-endemic setting
- Author
-
Roade, Luisa, Sulleiro, Elena, Bocanegra, Cristina, Salvador, Fernando, Trevino, Begona, Zarzuela, Francesc, Goterris, Lidia, Serre-Delcor, Nuria, Oliveira-Souto, Ines, Aznar, Maria Luisa, Pou, Diana, Sanchez-Montalva, Adrian, Bosch-Nicolau, Pau, Espinosa-Pereiro, Juan, and Molina, Israel
- Published
- 2023
3. Adherence and Toxicity during the Treatment of Latent Tuberculous Infection in a Referral Center in Spain.
- Author
-
Puyana Ortiz, Juan David, Garcés Rodríguez, Andrea Carolina, Aznar, María Luisa, Espinosa Pereiro, Juan, Sánchez-Montalvá, Adrián, Martínez-Campreciós, Joan, Saborit, Nuria, Rodrigo-Pendás, José Ángel, García Salgado, Guadalupe, Broto Cortes, Claudia, Delcor, Nuria Serre, Oliveira, Inés, Treviño Maruri, Begoña, Ciruelo, Diana Pou, Salvador, Fernando, Bosch-Nicolau, Pau, Torrecilla-Martínez, Irene, Zules-Oña, Ricardo, Tórtola Fernández, María Teresa, and Molina, Israel
- Published
- 2023
- Full Text
- View/download PDF
4. Efficacy and Safety of Tinzaparin in Prophylactic, Intermediate and Therapeutic Doses in Non-Critically Ill Patients Hospitalized with COVID-19: The PROTHROMCOVID Randomized Controlled Trial.
- Author
-
Muñoz-Rivas, Nuria, Aibar, Jesús, Gabara-Xancó, Cristina, Trueba-Vicente, Ángela, Urbelz-Pérez, Ana, Gómez-Del Olmo, Vicente, Demelo-Rodríguez, Pablo, Rivera-Gallego, Alberto, Bosch-Nicolau, Pau, Perez-Pinar, Montserrat, Rios-Prego, Mónica, Madridano-Cobo, Olga, Ramos-Alonso, Laura, Alonso-Carrillo, Jesús, Francisco-Albelsa, Iria, Martí-Saez, Edelmira, Maestre-Peiró, Ana, Méndez-Bailón, Manuel, Hernández-Rivas, José Ángel, and Torres-Macho, Juan
- Subjects
COVID-19 ,ARTIFICIAL respiration ,NONINVASIVE ventilation ,ADULT respiratory distress syndrome ,PSYCHOLOGICAL distress - Abstract
Hospitalized patients with COVID-19 are at increased risk of thrombosis, acute respiratory distress syndrome and death. The optimal dosage of thromboprophylaxis is unknown. The aim was to evaluate the efficacy and safety of tinzaparin in prophylactic, intermediate, and therapeutic doses in non-critical patients admitted for COVID-19 pneumonia. PROTHROMCOVID is a randomized, unblinded, controlled, multicenter trial enrolling non-critical, hospitalized adult patients with COVID-19 pneumonia. Patients were randomized to prophylactic (4500 IU), intermediate (100 IU/kg), or therapeutic (175 IU/kg) groups. All tinzaparin doses were administered once daily during hospitalization, followed by 7 days of prophylactic tinzaparin at discharge. The primary efficacy outcome was a composite endpoint of symptomatic systemic thrombotic events, need for invasive or non-invasive mechanical ventilation, or death within 30 days. The main safety outcome was major bleeding at 30 days. Of the 311 subjects randomized, 300 were included in the prespecified interim analysis (mean [SD] age, 56.7 [14.6] years; males, 182 [60.7%]). The composite endpoint at 30 days from randomization occurred in 58 patients (19.3%) of the total population; 19 (17.1 %) in the prophylactic group, 20 (22.1%) in the intermediate group, and 19 (18.5%) in the therapeutic dose group (p = 0.72). No major bleeding event was reported; non-major bleeding was observed in 3.7% of patients, with no intergroup differences. Due to these results and the futility analysis, the trial was stopped. In non-critically ill COVID-19 patients, intermediate or full-dose tinzaparin compared to standard prophylactic doses did not appear to affect the risk of thrombotic event, non-invasive ventilation, or mechanical ventilation or death. Trial RegistrationClinicalTrials.gov Identifier (NCT04730856). Edura-CT registration number: 2020-004279-42. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
5. Magnetic Bead Handling Using a Paper-Based Device for Quantitative Point-of-Care Testing.
- Author
-
Arias-Alpízar, Kevin, Sánchez-Cano, Ana, Prat-Trunas, Judit, Sulleiro, Elena, Bosch-Nicolau, Pau, Salvador, Fernando, Oliveira, Inés, Molina, Israel, Sánchez-Montalvá, Adrián, and Baldrich, Eva
- Subjects
POINT-of-care testing ,MALARIA ,IMAGE analysis ,LACTATE dehydrogenase ,IMAGING systems ,IMMUNOASSAY ,MILLING cutters - Abstract
Microfluidic paper-based analytical devices (μPADs) have been extensively proposed as ideal tools for point-of-care (POC) testing with minimal user training and technical requirements. However, most μPADs use dried bioreagents, which complicate production, reduce device reproducibility and stability, and require transport and storage under temperature and humidity-controlled conditions. In this work, we propose a μPAD produced using an affordable craft-cutter and stored at room temperature, which is used to partially automate a single-step colorimetric magneto-immunoassay. As a proof-of-concept, the μPAD has been applied to the quantitative detection of Plasmodium falciparum lactate dehydrogenase (Pf-LDH), a biomarker of malaria infection. In this system, detection is based on a single-step magneto-immunoassay that consists of a single 5-min incubation of the lysed blood sample with immuno-modified magnetic beads (MB), detection antibody, and an enzymatic signal amplifier (Poly-HRP). This mixture is then transferred to a single-piece paper device where, after on-chip MB magnetic concentration and washing, signal generation is achieved by adding a chromogenic enzyme substrate. The colorimetric readout is achieved by the naked eye or using a smartphone camera and free software for image analysis. This μPAD afforded quantitative Pf-LDH detection in <15 min, with a detection limit of 6.25 ng mL
−1 when the result was interpreted by the naked eye and 1.4 ng mL−1 when analysed using the smartphone imaging system. Moreover, the study of a battery of clinical samples revealed concentrations of Pf-LDH that correlated with those provided by the reference ELISA and with better sensitivity than a commercial rapid diagnostic test (RDT). These results demonstrate that magneto-immunoassays can be partly automated by employing a μPAD, achieving a level of handling that approaches the requirements of POC testing. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
6. COVID-19 Clinical Profile in Latin American Migrants Living in Spain: Does the Geographical Origin Matter?
- Author
-
Sempere, Abiu, Salvador, Fernando, Monforte, Arnau, Sampol, Júlia, Espinosa-Pereiro, Juan, Miarons, Marta, Bosch-Nicolau, Pau, Guillén-del-Castillo, Alfredo, Aznar, Maria Luisa, Campos-Varela, Isabel, Sánchez-Montalvá, Adrián, Leguízamo-Martínez, Lina María, Oliveira, Inés, Antón, Andrés, and Almirante, Benito
- Subjects
LATIN Americans ,INTENSIVE care units ,COVID-19 ,HOSPITAL patients ,HOSPITAL mortality - Abstract
The aim of this study was to describe and compare the clinical characteristics of hospitalized patients with COVID-19 pneumonia according to their geographical origin. This is a retrospective case-control study of hospitalized patients with confirmed COVID-19 pneumonia treated at Vall d'Hebron University Hospital (Barcelona) during the first wave of the pandemic. Cases were defined as patients born in Latin America and controls were randomly selected among Spanish patients matched by age and gender. Demographic and clinical variables were collected, including comorbidities, symptoms, vital signs and analytical parameters, intensive care unit admission and outcome at 28 days after admission. Overall, 1080 hospitalized patients were registered: 774 (71.6%) from Spain, 142 (13.1%) from Latin America and the rest from other countries. Patients from Latin America were considered as cases and 558 Spanish patients were randomly selected as controls. Latin American patients had a higher proportion of anosmia, rhinorrhea and odynophagia, as well as higher mean levels of platelets and lower mean levels of ferritin than Spanish patients. No differences were found in oxygen requirement and mortality at 28 days after admission, but there was a higher proportion of ICU admissions (28.2% vs. 20.2%, p = 0.0310). An increased proportion of ICU admissions were found in patients from Latin America compared with native Spanish patients when adjusted by age and gender, with no significant differences in in-hospital mortality. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
7. Treatment of Complex Cutaneous Leishmaniasis with Liposomal Amphotericin B.
- Author
-
Ubals, Maria, Bosch-Nicolau, Pau, Sánchez-Montalvá, Adrián, Salvador, Fernando, Aparicio-Español, Gloria, Sulleiro, Elena, Silgado, Aroa, Soriano-Arandes, Antoni, Espiau, Maria, Ferrer, Berta, Pou, Diana, Treviño, Begoña, Molina, Israel, and García-Patos, Vicente
- Subjects
AMPHOTERICIN B ,CUTANEOUS leishmaniasis ,TREATMENT failure ,MEDICAL personnel ,LEISHMANIASIS ,MEDICATION safety ,DRUG utilization ,MUCORMYCOSIS - Abstract
Background: There is no consensus for the best treatment of complex cutaneous leishmaniasis (CL). We aimed to describe a cohort of CL, focusing on liposomal amphotericin B (L-AmB) treatment outcome. Methods: We performed a retrospective study in Vall d'Hebron University Hospital (Barcelona, Spain). All patients with parasitologically proven CL diagnosed from 2012 to 2018 were included. Results: The analysis included 41 patients with CL. The median age was 39 years (IQR 12- 66); 12 (29%) were children, and 29 (71%) were men. Regarding treatment, 24 (59%) received local treatment, whereas 17 (41%) had complex CL and were offered intravenous systemic treatment. Sixteen patients received L-AmB; eight (50%) had adverse events, and three (19%) discontinued treatment for safety reasons. All cases were considered cured within the first year post-treatment. Conclusions: L-AmB for complex CL showed no treatment failures, offering an alternative treatment option for patients with complex CL. Clinicians should pay close attention to the potential adverse events of L-AmB and adopt an active drug safety surveillance scheme to rapidly detect reversible side effects. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
8. Blastocystis sp. Carriage and Irritable Bowel Syndrome: Is the Association Already Established?
- Author
-
Salvador, Fernando, Lobo, Beatriz, Goterris, Lidia, Alonso-Cotoner, Carmen, Santos, Javier, Sulleiro, Elena, Bailo, Begoña, Carmena, David, Sánchez-Montalvá, Adrián, Bosch-Nicolau, Pau, Espinosa-Pereiro, Juan, Fuentes, Isabel, and Molina, Israel
- Subjects
IRRITABLE colon ,DEFECATION ,BLASTOCYSTIS ,INTESTINAL parasites ,INTESTINAL diseases ,PARASITIC diseases ,VISCERAL pain - Abstract
Simple Summary: The intestinal protist Blastocystis sp. is one of the most common intestinal parasites observed in humans, and has a worldwide distribution, being more prevalent in developing countries. Although this parasite has been described decades ago, the pathogenic potential it is still not understood completely. It has been suggested that Blastocystis sp. could be related with irritable bowel syndrome, a functional gastrointestinal disorder characterized by abdominal pain, discomfort with defecation, and changes in the frequency or form of stool. In our study, we compare a group of patients with irritable bowel syndrome with a group of healthy volunteers; no differences regarding the occurrence of Blastocystis sp. detection was found between both groups. Background: The aim of the present study is to describe the occurrence of Blastocystis sp. detection among asymptomatic subjects and patients with irritable bowel syndrome in order to evaluate the potential association between irritable bowel syndrome and the parasitic infection. Methods: Cross-sectional study where adult patients with irritable bowel syndrome diagnosed according to Rome IV criteria were included. A control group was formed by asymptomatic subjects older than 18 years. Exclusion criteria were: immunosuppressive condition or having received any drug with demonstrated activity against Blastocystis sp. within the last 6 months before study inclusion. Epidemiological and clinical information was collected from all included participants. Two stool samples were obtained from all participants: one sample for microscopic examination and one sample for Blastocystis sp. PCR detection. Blastocystis sp. infection was defined by the positivity of any of the diagnostic techniques. Results: Seventy-two participants were included (36 asymptomatic subjects and 36 patients with irritable bowel syndrome). Thirty-five (48.6%) were men, and median age of participants was 34 (IQR 29–49) years. The overall rate of Blastocystis sp. carriage was 27.8% (20/72). The prevalence assessed through microscopic examination was 22.2% (16/72), while the prevalence measured by PCR was 15.3% (11/72). When comparing the presence of Blastocystis sp. between asymptomatic subjects and IBS patients, we did not find any statistically significant difference (36.1% vs. 19.4% respectively, p = 0.114). Conclusions: regarding the occurrence of Blastocystis sp., no differences were found between asymptomatic participants and patients with irritable bowel disease irrespective of the diagnostic technique performed. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.